FLOHR, ALEXANDER,JAKOB-ROETNE, ROLAND,NORCROSS, ROGER DAVID,RIEMER, CLAUS
申请号：
CA2524366
公开号：
CA2524366C
申请日:
2004.05.14
申请国别(地区):
CA
年份:
2012
代理人:
摘要：
The invention relates to compounds of the general formula (I) wherein R1 is1,4-dioxepanyl or tetrahydropyran-4-yl； R2 is -N(R)-(CH2)n,-5-or 6 memberednon aromatic heterocycle, optionally substituted by one or more substituents,selected from the group consisting of lower alkyl or -NR2, or is - (CH2)n-5-or6 membered non aromatic heterocycle, optionally substituted by -(CH2)n-OH,lower alkyl, lower alkoxy, or is -CH2)n-5-or 6 membered aromatic heterocycle,optionally substituted by lower alkyl, lower alkoxy, halogen, halogen-loweralkyl, -CH2N(R)(CH2)20CH3, -N(R)(CH2)20CH3, -CH2-morpholinyl or -CH2-pyrrolidinyl or is (CH2)n-cycloalkyl, optionally substituted by hydroxy, or is-N(R)-cycloalkyl, optionally substituted by hydroxy or lower alkyl, or isphenyl, optionally substituted by lower alkoxy, halogen, halogen-lower alkyl,lower alkyl, -CH2-pyrrolidin-1-yl, -CH2-morpholinyl, -CH2N(R)(CH2)20CH3 or -CH2-N(R)C(O)-lower alkyl, or is 1,4-dioxa-8-aza-spiro[4,5]decane, or is 2-oxa-5-aza-bicyclo[2.2.1]heptane, or is I-oxa-8-aza-spiro[4,5]decane, or is -N(R)-7-oxa-bicyclo [2.2. 11 hept-2-yl, or is 2-aza-bicyclo[2.2.2]decane； R ishydrogen or lower alkyl； n is 0 or 1； and pharmaceutically acceptable acidaddition salts thereof for the treatment of diseases, which relate to the A2Areceptor.
